Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2022-02-11 4:48 pm Purchase | 13G | ADDEX THERAPEUTICS LTD ADS ADXN | New Leaf Biopharma Opportunities I L.P. | 2,366,293 4.5% | 50,000 (+2.16%) | View |
| 2022-01-10 1:15 pm Unchanged | 13D | ADDEX THERAPEUTICS LTD ADS ADXN | Growth Equity Opportunities Fund IV LLC | 7,704,600 20.4% | 0 (Unchanged) | View |
| 2021-09-08 06:01 am Purchase | 13D | ADDEX THERAPEUTICS LTD ADS ADXN | Dyer Timothy Mark | 3,630,988 9.73% | 763,439 (+26.62%) | View |
| 2021-02-16 4:19 pm Purchase | 13G | ADDEX THERAPEUTICS LTD ADS ADXN | CAXTON CORP | 2,316,293 8.4% | 2,316,293 (New Position) | View |
| 2021-02-12 3:53 pm Purchase | 13G | ADDEX THERAPEUTICS LTD ADS ADXN | CREDIT SUISSE AG | 1,874,245 5.71% | 1,874,245 (New Position) | View |
| 2021-02-10 5:30 pm Purchase | 13G | ADDEX THERAPEUTICS LTD ADS ADXN | New Leaf Biopharma Opportunities I L.P. | 2,316,293 7.1% | 2,316,293 (New Position) | View |
| 2021-01-21 6:47 pm Purchase | 13D | ADDEX THERAPEUTICS LTD ADS ADXN | Growth Equity Opportunities Fund IV LLC | 7,704,600 21.5% | 7,704,600 (New Position) | View |
| 2020-11-03 4:10 pm Purchase | 13D | ADDEX THERAPEUTICS LTD ADS ADXN | Dyer Timothy Mark | 2,867,549 8.73% | 2,867,549 (New Position) | View |